Fig. 1: Genetic alterations of the PI3K- mTOR- AKT pathway in squamous cell lung cancer. | Cancer Gene Therapy

Fig. 1: Genetic alterations of the PI3K- mTOR- AKT pathway in squamous cell lung cancer.

From: Targeting mTORC2 in lung squamous cell carcinoma improves anti-tumor immunity through the PSGL-1-VISTA axis

Fig. 1

A Molecular alteration in non-small cell lung cancer (NSCLC) using the human gene set for REACTOME_PI3K_AKT_SIGNALING_IN_CANCER pathway from 5 cancer datasets [NSCLC: TCGA PanCancer Atlas (n = 1144); LUSC: CPTAC (n = 80), TCGA Firehose Legacy (n = 511); LUAD: CPTAC (n = 110), TCGA Firehose Legacy (n = 586)] using tools developed by cBioPortal. B Analysis of mTORC2 related genes (mTORC2 signature: PIK3CA, RICTOR, PTEN, AKT1-3) that are amplified, deleted, and mutated from the LUSC studies in panel (A) above [LUSC: CPTAC (n = 80); TCGA Firehose Legacy (n = 511)]. Kaplan-Meier (KM) of stage II-IV plot displaying the probability of relapse-free survival (C) and overall survival (D) with association of the mTORC2 related genes illustrated in (B) using lung squamous cell carcinoma RNA-seq dataset (n = 141, relapse-free survival and n = 249, overall survival) downloaded from kmplot.com.

Back to article page